Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis

Colm Elliott(NeuroRx Research (Canada)), David A. Rudko(Montreal Neurological Institute and Hospital), Douglas L. Arnold(NeuroRx Research (Canada)), Dumitru Fetco(NeuroRx Research (Canada)), Ahmed M. Elkady(Montreal Neurological Institute and Hospital), David Araújo(NeuroRx Research (Canada)), Bing Zhu(Biogen (United States)), Arie Gafson(Biogen (United States)), Zhe Tian(Biogen (United States)), Shibeshih Belachew(Biogen (United States)), Daniel P. Bradley(Biogen (United States)), Elizabeth Fisher(Biogen (United States))
Multiple Sclerosis Journal
April 10, 2023
Cited by 61Open Access
Full Text

Abstract

BACKGROUND: Paramagnetic rim lesions (PRLs) and slowly expanding lesions (SELs) have been posited as markers of chronic active lesions (CALs). OBJECTIVE: To assess the lesion-level concordance of PRLs and SELs in MS and to characterize changes in brain tissue integrity in CALs over time. METHODS: MRIs were analyzed from a substudy of AFFINITY [NCT03222973], a phase 2 trial of opicinumab in relapsing MS. Assessments included (1) identification of SELs based on longitudinal MRIs over 72 weeks, and identification of PRLs on susceptibility-weighted imaging (SWI) filtered phase images at week 72; (2) evaluation of subject-level correlation of SEL and PRL counts, volumes, and degree of lesion-level overlap between SELs and PRLs; and (3) characterization of tissue integrity over time in overlapping and non-overlapping SELs and PRLs. RESULTS: In 41 subjects, 119 chronic PRLs and 267 SELs were detected. Of 119 (39.5%) chronic PRLs, 47 co-localized with a SEL; 46/267 (17.2%) SELs co-localized with a PRL. PRLs co-localized with SELs showed expansion and worsening microstructural damage over time. SELs with and without co-localization with PRLs showed ongoing tissue damage. CONCLUSIONS: Chronic MS lesions identified as both PRL and SEL were associated with the most severe accumulation of tissue damage. TRIAL REGISTRATION: AFFINITY [NCT03222973].


Related Papers